Regulation of TGF-β signaling by SMADs and its roles in tissue fibrosis

Current Signal Transduction Therapy

Volumn 3, Issue 1, 2008, Pages 1-6

  Fukasawa, Hirotaka ^a,b   Yamamoto, Tatsuo ^a   Kitagawa, Masatoshi ^a   Hishida, Akira ^a  

^a HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

c Ski (Sloan Kettering Institute proto oncogene); Smad; Smad ubiquitination regulatory factor (Smurf); SnoN (ski related novel gene N) and ubiquitin proteasome system; Transforming growth factor (TGF )

Indexed keywords

CELL SURFACE RECEPTOR; CYTOKINE; MATRIX PROTEIN; PROTEASOME; PROTEIN SERINE THREONINE KINASE; SMAD PROTEIN; SMAD2 PROTEIN; SMAD3 PROTEIN; SMAD7 PROTEIN; TRANSCRIPTION FACTOR; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA RECEPTOR; UBIQUITIN; UBIQUITIN PROTEIN LIGASE E3;

CELL SURFACE; COMPLEX FORMATION; DISEASE COURSE; DOWN REGULATION; EXTRACELLULAR MATRIX; FIBROGENESIS; FIBROSIS; GENE TARGETING; GENETIC TRANSCRIPTION; HUMAN; IMMUNOMODULATION; KIDNEY FIBROSIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTO ONCOGENE; REGULATORY MECHANISM; REVIEW; SCLERODERMA; SIGNAL TRANSDUCTION; TRANSCRIPTION INITIATION; TRANSCRIPTION REGULATION; UBIQUITINATION;

EID: 39449117745     PISSN: 15743624     EISSN: None     Source Type: Journal    
DOI: 10.2174/157436208783334259     Document Type: Review

References (74)

1. Massague J. TGF-beta signal transduction. Annu Rev Biochen, 1998; 67: 753-91.
2. Border WA, Ruoslahti E. Transforming growth factor-beta in disease: the dark side of tissue repair. J Clin Invest 1992; 90: 1-7.
3. Sporn MB, Roberts AB. The transforming growth factor-betas: past, present, and future. Ann N Y Acad Sci 1990; 593: 1-6.
4. Shull MM, Ormsby I, Kier AB, et al. Targeted disruption of the mouse transforming growth factor-beta 1 gene results in multifocal inflammatory disease. Nature 1992; 359: 693-9.
5. Sanford LP, Ormsby I, Gittenberger-de Groot AC, et al. TGFbeta2 knockout mice have multiple developmental defects that are non-overlapping with other TGFbeta knockout phenotypes. Development 1997; 124: 2659-70.
6. Ledbetter S, Kurtzberg L, Doyle S, Pratt BM. Renal fibrosis in mice created with human recombinant transforming growth factor-beta2. Kidney Int 2000; 58: 2367-76.
7. Proetzel G, Pawlowski SA, Wiles MV, et al. Transforming growth factor-beta 3 is required for secondary palate fusion. Nat Genet 1995; 11: 409-14.
8. O'Kane S, Ferguson MW. Transforming growth factor beta s and wound healing. Int J Biochem Cell Biol 1997; 29: 63-78.
9. Massague J, Wotton D. Transcriptional control by the TGF-beta/Smad signaling system. EMBO J 2000; 19: 1745-54.
10. Oh SP, Seki T, Goss KA, et al. Activin receptor-like kinase 1 modulates transforming growth factor-beta 1 signaling in the regulation of angiogenesis. Proc Natl Acad Sci U S A 2000; 97: 2626-31.
11. Huse M, Chen YG, Massague J, Kuriyan J. Crystal structure of the cytoplasmic domain of the type I TGF beta receptor in complex with FKBP12. Cell 1999; 96: 425-36.
12. Persson U, Izumi H, Souchelnytskyi S, et al. The L45 loop in type I receptors for TGF-beta family members is a critical determinant in specifying Smad isoform activation. FEBS Lett 1998; 434: 83-7.
13. Ehrlich M, Shmuely A, Henis YI. A single internalization signal from the dileucine family is critical for constitutive endocytosis of the type II TGF-beta receptor. J Cell Sci 2001; 114: 1777-86.
14. Hayes S, Chawla A, Corvera S. TGF beta receptor internalization into EEA1-enriched early endosomes: role in signaling to Smad2. J Cell Biol 2002; 158: 1239-49
15. Penheiter SG, Mitchell H, Garamszegi N, Edens M, Dore JJ, Jr., Leof EB. Internalization-dependent and -independent requirements for transforming growth factor beta receptor signaling via the Stand pathway. Mol Cell Biol 2002; 22: 4750-9.
16. Di Guglielmo GM, Le Roy C, Goodfellow AF, Wrana JL. Distinct endocytic pathways regulate TGF-beta receptor signalling and turnover. Nat Cell Biol 2003; 5: 410-21.
17. Lu Z, Murray Yr, Luo W, et al. Transforming growth factor beta activates Smad2 in the absence of receptor endocytosis. J Biol Chem 2002; 277: 29363-8.
18. Attisano L, Wrana JL. Mads and Smads in TGF beta signalling. Curr Opin Cell Biol 1998; 10: 188-94.
19. Tsukazaki T, Chiang TA, Davison AF, Attisano L, Wrana JL. SARA, a FYVE domain protein that recruits Smad2 to the TGFbeta receptor. Cell 1998; 95: 779-91.
20. Dong C, Li Z, Alvarez R, Jr., Feng XH, Goldschmidt-Clermont PJ. Microtubule binding to Smads may regulate TGF beta activity. Mol Cell 2000; 5: 27-34.
21. Imamura T, Takase M, Nishihara A, et al. Smad6 inhibits signalling by the TGF-beta superfamily. Nature 1997; 389: 622-6.
22. Nakao A, Afrakhte M, Moren A, et al. Identification of Smad7, a TGFbeta-inducible antagonist of TGF-beta signalling. Nature 1997; 389: 631-5.
23. Hayashi H, Abdollah S, Qiu Y, et al. The MAD-related protein Smad7 associates with the TGFbeta peceptor and functions as an antagonist of TGFbeta signaling. Cell 1997; 89: 1165-73.
24. Nagarajan RP, Zhang J, Li W, Chen Y. Regulation of Smad7 promoter by direct association with Smad3 and Smad4. J Biol Chem 1999; 274: 33412-8.
25. Kavsak P, Rasmussen RK, Causing CG, et al. Smad7 binds to Smurf2 to form an E3 ubiquitin ligase that targets the TGF beta receptor for degradation. Mol Cell 2000; 6: 1365-75.
26. Ebisawa T, Fukuchi M, Murakami G, et al. Smurf1 interacts with transforming growth factor-beta type I receptor through Smad7 and induces receptor degradation. J Biol Chem 2001; 276: 12477-80.
27. Gronroos E, Hellman U, Heldin CH, Ericsson J, Control of Smad7 stability by competition between acetylation and ubiquitination. Mol Cell 2002; 10: 483-93.
28. Kawabata M, Inoue H, Hanyu A, Imamura T, Miyazono K. Smad proteins exist as monomers in vivo and undergo homo- and hetero-oligomerization upon activation by serine/threonine kinase receptors. EMBO J 1998; 17: 4056-65.
29. Qin BY, Chacko BM, Lam SS, de Caestecker MP, Correia JJ, Lin K. Structural basis of Smad1 activation by receptor kinase phosphorylation. Mol Cell 2001; 8: 1303-12.
30. Wu JW, Hu M, Chai J, et al. Crystal structure of a phosphorylated Smad2. Recognition of phosphoserine by the MH2 domain and insights on Smad function in TGF-beta signaling. Mol Cell 2001; 8: 1277-89.
31. Kurisaki A, Kose S, Yoneda Y, Heldin CH, Moustakas A. Transforming growth factor-beta induces nuclear import of Smad3 in an importin-beta1 and Ran-dependent manner. Mol Biol Cell 2001; 12: 1079-91.
32. Xiao Z, Watson N, Rodriguez C, Lodish HF. Nucleocytoplasmic shuttling of Smad1 conferred by its nuclear localization and nuclear export signals. J Biol Chem 2001; 276: 39404-10.
33. Watanabe M, Masuyama N, Fukuda M, Nishida E. Regulation of intracellular dynamics of Smad4 by its leucine-rich nuclear export signal. EMBO Rep 2000; 1: 176-82.
34. Monteleone G, Kumberova A, Croft NM, McKenzie C, Steer HW, MacDonald TT. Blocking Smad7 restores TGF-beta1 signaling in chronic inflammatory bowel disease. J Clin Invest 2001; 108: 601-9.
35. Dong C, Zhu S, Wang T, et al. Deficient Smad7 expression: a putative molecular defect in scleroderma. Proc Natl Acad Sci U S A 2002; 99: 3908-13.
36. Wang B, Hao J, Jones SC, Yee MS, Roth JC, Dixon IM. Decreased Smad 7 expression contributes to cardiac fibrosis in the infarcted rat heart. Am J Physiol Heart Circ Physiol 2002; 282: H1685-96.
37. Fukasawa H, Yamamoto T, Togawa A, et al. Down-regulatim of Smad7 expression by ubiquitin-dependent degradation contributes to renal fibrosis in obstructive nephropathy in mice. Proc Natl Acad Sci U S A 2004; 101: 8687-92.
38. Tahashi Y, Matsuzaki K, Date M, et al. Differential regulation of TGF-beta signal in hepatic stellate cells between acute and chronic rat liver injury. Hepatology 2002; 35: 49-61.
39. Nakao A, Fujii M, Matsumura R, et al. Transient gene transfer and expression of Smad7 prevents bleomycin-induced lung fibrosis in mice. J Clin Invest 1999; 104: 5-11.
40. Lan HY, Mu W, Tomita N, et al. Inhibition of renal fibrosis by gene transfer of inducible Smad7 using ultrasound-microbubble system in rat UUO model. J Am Soc Nephrol 2003; 14: 1535-48.
41. Pouponnot C, Jayaraman L, Massague J. Physical and functional interaction of SMADs and p300/CBP. J Biol Chem 1998; 273: 22865-8.
42. Wotton D, Lo RS, Lee S, Massague J. A Smad transcriptional corepressor. Cell 1999; 97: 29-39.
43. Li Y, Turck CM, Teumer JK, Stavnezer E. Unique sequence, ski, in Sloan-Kettering avian retroviruses with properties of a new cell-derived oncogene. J Virol 1986; 57: 1065-72.
44. Nomura N, Sasamoto S, Ishii S, Date T, Matsui M, Ishizaki R. Isolation of human cDNA clones of ski and the ski-related gene, sno. Nucleic Acids Res 1989; 17: 5489-500.
45. Pearson-White S, Crittenden R. Proto-oncogene Sno expression, alternative isoforms and immediate early serum response. Nucleic Acids Res 1997; 25: 2930-7.
46. Liu X, Sun Y, Weinberg RA, Lodish HF. Ski/Sno and TGF-beta signaling. Cytokine Growth Factor Rev 2001; 12: 1-8.
47. Nomura T, Khan MM, Kaul SC, et al. Ski is a component of the histone deacetylase complex required for transcriptional repression by Mad and thyroid hormone receptor. Genes Dev 1999; 13: 412-23.
48. Stroschein SL, Wang W, Zhou S, Zhou Q, Luo K. Negative feedback regulation of TGF-beta signaling by the SnoN oncoprotein. Science 1999; 286: 771-4.
49. Luo K, Stroschein SL, Wang W, et al. The Ski oncoprotein interacts with the Smad proteins to repress TGFbeta signaling. Genes Dev 1999; 13: 2196-206.
50. Sun Y, Liu X, Ng-Eaton E, Lodish HF, Weinberg RA. SnoN and Ski protooncoproteins are rapidly degraded in response to transforming growth factor beta signaling. Proc Natl Acad Sci U S A 1999; 96: 12442-7.
51. Stroschein SL, Bonni S, Wrana JL, Luo K. Smad3 recruits the anaphase-promoting complex for ubiquitination and degradation of SnoN. Genes Dev 2001; 15: 2822-36.
52. Yang J, Zhang X, Li Y, Liu Y. Downregulation of Smad transcriptional corepressors SnoN and Ski in the fibrotic kidney: an amplification mechanism for TGF-beta1 signaling. J Am Soc Nephrol 2003; 14: 3167-77.
53. Dennler S, Itoh S, Vivien D, ten Dijke P, Huet S, Gauthier JM. Direct binding of Smad3 and Smad4 to critical TGF beta-inducible elements in the promoter of human plasminogen activator inhibitor-type 1 gene. EMBO J 1998; 17: 3091-100.
54. Jonk LJ, Itoh S, Heldin CH, ten Dijke P, Kruijer W. Identification and functional characterization of a Smad binding element (SBE) in the JunB promoter that acts as a transforming growth factor-beta, activin, and bone morphogenetic protein-inducible enhancer. J Biol Chem 1998; 273: 21145-52.
55. Chen SJ, Yuan W, Mori Y, Levenson A, Trojanowska M, Varga J. Stimulation of type I collagen transcription in human skin fibroblasts by TGF-beta: involvement of Smad 3. J Invest Dermatol 1999; 112: 49-57.
56. Vindevoghel L, Lechleider RJ, Kon A, et al. SMAD3/4-dependent transcriptional activation of the human type VII collagen gene (COL7A1) promoter by transforming growth factor beta. Proc Natl Acad Sci U S A 1998; 95: 14769-74.
57. Feng XH, Lin X, Derynck R. Smad2, Smad3 and Smad4 cooperate with Sp1 to induce p15(Ink4B) transcription in response to TGF-beta. EMBO J 2000; 19: 5178-93.
58. Holmes A, Abraham DJ, Sa S, Shiwen X, Black CM, Leask A. CTGF and SMADs, maintenance of scleroderma phenotype is independent of SMAD signaling. J Biol Chem 2001; 276: 10594-601.
59. Verrecchia F, Chu ML, Mauviel A. Identification of novel TGF-beta /Smad gene targets in dermal fibroblasts using a combined cDNA microarray/ promoter transactivation approach. J Biol Chem 2001; 276: 17058-62.
60. Hershko A, Ciechanover A. The ubiquitin system. Annu Rev Biochem 1998; 67: 425-79.
61. Bonni S, Wang HR, Causing CG, et al. TGF-beta induces assembly of a Smad2-Smurf2 ubiquitin ligase complex that targets SnoN for degradation. Nat Cell Biol 2001; 3: 587-95.
62. Zhu H, Kavsak P, Abdollah S, Wrana JL, Thomsen GH. A SMAD ubiquitin ligase targets the BMP pathway and affects embryonic pattern formation. Nature 1999; 400: 687-93.
63. Zhang Y, Chang C, Gehling DJ, Hemmati-Brivanlou A, Derynck R. Regulation of Smad degradation and activity by Smurf2, an E3 ubiquitin ligase. Proc Natl Acad Sci U S A 2001; 98: 974-9.
64. Lin X, Liang M, Feng XH. Smurf2 is a ubiquitin E3 ligase mediating proteasome-dependent degradation of Smad2 in transforming growth factor-beta signaling. J Biol Chem 2000; 275: 36818-22
65. Asano Y, Ihn H, Yamane K, Kubo M, Tamaki K. Impaired Smad7-Smurf-mediated negative regulation of TGF-beta signaling in scleroderma fibroblasts. J Clin Invest 2004; 113: 253-64.
66. Ohashi N, Yamamoto T, Uchida C, et al. Transcriptional induction of Smurf2 ubiquitin ligase by TGF-beta. FEBS Lett 2005; 579: 2557-63.
67. Koinuma D, Shinozaki M, Komuro A, et al. Arkadia amplifies TGF-beta superfamily signalling through degradation of Smad7. EMBO J 2003; 22. 6458-70.
68. Liu W, Rui H, Wang J, et al. Axin is a scaffold protein in TGF-beta signaling that promotes degradation of Smad7 by Arkadia. EMBO J 2006; 25: 1646-58.
69. Liu FY, Li XZ. The roles of Arkadia in renal tubular epithelial to mesenchymal transition. Med Hypotheses 2006; 67: 1205-7.
70. Izzi L, Attisano L. Regulation of the TGFbeta signalling pathway by ubiquitin-mediated degradation. Oncogene 2004; 23: 2071-8.
71. Border WA, Okuda S, Languino LF, Sporn MB, Ruoslahti E. Suppression of experimental glomerulonephritis by antiserum against transforming growth factor beta 1. Nature 1990; 346: 371-4.
72. Ziyadeh FN, Hoffman BB, Han DC, et al. Long-term prevention of renal insufficiency, excess matrix gene expression, and glomerular mesangial matrix expansion by treatment with monoclonal antitransforming growth factor-beta antibody in db/db diabetic mice. Proc Natl Acad Sci U S A 2000; 97: 8015-20.
73. Akagi Y, Isaka Y, Arai M, et al. Inhibition of TGF-beta 1 expression by antisense oligonucleotides suppressed extracellular matrix accumulation in experimental glomerulonephritis. Kidney Int 1996; 50: 148-55.
74. Border WA, Noble NA, Yamamoto T, et al. Natural inhibitor of transforming growth factor-beta protects against scarring in experimental kidney disease. Nature 1992; 360: 361-4.